Roxithromycin Powder Veterinary Medicine CAS 80214-83-1 Raw Materials

CAS: 80214-83-1

MF: C41H76N2O15

MW: 837.05

EINECS: 617-007-5

Specification​: 99% min Roxithromycin 

Sample: Roxithromycin Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Portal:https://henrikang.en.made-in-china.com/

Roxithromycin Powder Usage and Synthesis.

Roxithromycin Powder is the most commonly used broad-spectrum and highly effective anti-inflammatory drug, Veterinary Medicine Roxithromycin is a member of the family of broad-spectrum antimicrobials. member of the family of broad-spectrum antimicrobials. 

Roxithromycin Raw Materials Generic names include Roxithromycin capsules, Roxithromycin enteric-coated tablets, Roxithromycin dispersible tablets, Roxithromycin Powder is commonly used in pharyngitis and tonsillitis caused by Streptococcus pyogenes, various inflammations caused by sensitive bacteria. sensitive bacteria.Roxithromycin Raw Materials is white crystalline powder, odorless, bitter taste. It is a new generation of macrolide antibiotic.

Roxithromycin is a semi-synthetic 14-membered ring macrolide antibiotic. Its mechanism of action is similar to that of erythromycin, and its in vivo antimicrobial effect is 1-4 times stronger than that of erythromycin, its effect on Gram-positive bacteria is slightly worse than that of erythromycin, its effect on Legionella pneumophila is stronger than that of erythromycin, and its antimicrobial effect on Chlamydia pneumoniae, Mycoplasma pneumoniae, and Urea urealytica is similar to that of erythromycin, or a little stronger.

Roxithromycin is a semi-synthetic macrolide antibiotic. It can pass through the bacterial cell membrane and achieve antibacterial effect by inhibiting bacterial protein synthesis.

Uses and functions of Roxithromycin Powder.

This product is suitable for pharyngitis and tonsillitis caused by Streptococcus pyogenes, sinusitis, otitis media, acute bronchitis, acute exacerbation of chronic bronchitis caused by sensitive bacteria, pneumonia caused by Mycoplasma pneumoniae or Chlamydia pneumoniae; Chlamydia trachomatis-induced infections of the genitourinary system (urethritis and cervicitis).

Infections of the soft tissues of the skin and other parts of the body caused by sensitive bacteria; also used for non-specific and gonococcal genital infections.

Infections caused by Legionella. Pediatric infections. Roxithromycin is characterized by acid resistance and good oral absorption, T1/2 for 12 to 14 hours, to be more than 6 times higher than erythromycin.

Widely distributed in the body, in the upper and lower respiratory tract, the reproductive tract and the skin can reach a high concentration and maintain a long time. Most of them are metabolized in the body.

Evaluation of clinical application of Roxithromycin: the clinical and bacteriologic cure rate of chlamydial urethritis and cervicitis is 93% to 97%, the efficacy of genital infections is similar to that of doxycycline, the cure rate of skin infections reaches more than 90%, and the effective rate of treating respiratory infections is 83% and 50%, and the effective rate of pneumonia and dental infections is 79% and 85%.

Macrolide antibiotic, a derivative of erythromycin, with similar antibacterial spectrum and erythromycin, but 6 times stronger action than erythromycin, high bioavailability.

It is used for respiratory tract infections, such as pneumonia, acute bronchitis, chronic bronchitis acute infection, atypical pneumonia, and genitourinary infections, skin and soft tissue infections, etc. It has good therapeutic effect and tolerance, and the adverse effects are smaller than erythromycin.

Pharmacological Effects of Roxithromycin Powder.

Roxithromycin Powder can cross the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome in the vicinity of the donor ("P" position), blocking the transfer of ribonucleic acid (RNA) to the "P" position, and at the same time blocking the transfer of polypeptide from the acceptor position ("A" position) to the "P" position, thus inhibiting the synthesis of bacterial proteins, thus exerting antibacterial effects. It also blocks the transfer of polypeptide chain from the acceptor site ("A" site) to the "P" site, thus inhibiting bacterial protein synthesis and thus playing an antibacterial role.

It is characterized by its rapid entry into macrophages, alveolar cells and neutrophils. In vitro studies have confirmed that roxithromycin has a broad antibacterial spectrum, with antibacterial activity against a variety of streptococci (including Streptococcus A, B, C and Streptococcus pneumoniae, except G and enterococci), Streptococcus pneumoniae, Streptococcus aureus, Staphylococcus aureus (except MRSA), Staphylococcus epidermidis, Legionella pneumophila, Haemophilus ducreyi, Chlamydia trachomatis, Mycoplasma pneumoniae, and oral or vaginal anaerobes almost the same as erythromycin, and Cataplanham.

The antibacterial activity is almost the same as that of erythromycin, Catabranococcus is highly sensitive to Roxithromycin, and has inhibitory effect on Campylobacter, Bordetella pertussis, Haemophilus influenzae, Mycobacterium tuberculosis, Mycobacterium diphtheriae, and it has no antibacterial activity on other Gram-negative bacteria.

The in vivo antibacterial activity of this product is significantly stronger than erythromycin, and the efficacy of Chlamydia, Mycoplasma, Ureaplasma urealyticum, Treponema pallidum and Legionella infections is remarkable. It is weaker against Helicobacter, Gonococcus, Meningococcus, B. pertussis and so on. Certain bacteria are cross-resistant to erythromycin and this product.

Production method of Roxithromycin Powder.

Take erythromycin as raw material, react with hydroxylamine hydrochloride in triethylamine and methanol to produce oxime, then react with methoxyethoxymethyl chloride in acetone to obtain Roxithromycin.